Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

44.77USD
1:30am IST
Change (% chg)

$-0.04 (-0.09%)
Prev Close
$44.81
Open
$44.71
Day's High
$44.99
Day's Low
$44.59
Volume
1,318,569
Avg. Vol
2,551,381
52-wk High
$45.84
52-wk Low
$36.76

ABT.N

Chart for ABT.N

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $77,431.57
Shares Outstanding(Mil.): 1,728.00
Dividend: 0.26
Yield (%): 2.37

Financials

  ABT.N Industry Sector
P/E (TTM): 62.58 28.87 29.67
EPS (TTM): 0.72 -- --
ROI: 2.73 13.62 13.13
ROE: 5.09 14.52 14.27

Higher heart risk seen with Abbott dissolving stent after two years: study

WASHINGTON Patients who received Abbott Laboratories' novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company's widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday.

18 Mar 2017

UPDATE 1-Higher heart risk seen with Abbott dissolving stent after 2 years -study

WASHINGTON, March 18 Patients who received Abbott Laboratories' novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company's widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday.

18 Mar 2017

Higher heart risk seen with Abbott dissolving stent after 2 years -study

WASHINGTON, March 18 Patients who received Abbott Laboratories' novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company's widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday.

18 Mar 2017

BRIEF-Abbott Laboratories says CEO Miles White total compensation for 2016 $20.3 mln vs. $19.4 mln in 2015

* Abbott laboratories says chairman and ceo miles white total compensation for 2016 $20.3 million versus. $19.4 million in 2015 Source text for Eikon: Further company coverage:

17 Mar 2017

BRIEF-Abbott says findings from Lotus I study may have important implications for women undergoing IVF

* Abbott Laboratories - findings from Lotus I study have potential to have important implications for women undergoing IVF

08 Mar 2017

BRIEF-FTC approves final order settling charges for Abbott's deal with St. Jude Medical

* Approved final order settling charges that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would likely be anticompetitive

23 Feb 2017

BRIEF-Abbott Laboratories commences exchange offers, consent solicitations for St. Jude Medical notes

* Abbott laboratories - Abbott commences exchange offers and consent solicitations for St. Jude Medical LLC notes Source text for Eikon: Further company coverage:

21 Feb 2017

MEDIA-Abbott likely to withdraw high-end stents in India - Business Standard

- Note: Reuters has not verified this story and does not vouch for its accuracy

21 Feb 2017

BRIEF-Abbott Laboratories says board of directors shall consist of 12 persons from 11

* Abbott Laboratories-on Feb 16, amended by-laws to provide that co's board of directors shall consist of 12 persons, effective as of February 16, 2017

18 Feb 2017

BRIEF-ABBOTT SETS QUARTERLY DIVIDEND OF $0.265 PER SHARE

* SETS QUARTERLY DIVIDEND OF $0.265 PER SHARE Source text for Eikon: Further company coverage:

17 Feb 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $125.90 -0.36
Pfizer Inc. (PFE.N) $34.29 -0.18
Novartis AG (NOVN.S) CHF74.15 +0.75
Merck & Co., Inc. (MRK.N) $63.28 -0.22
Sanofi SA (SASY.PA) €83.30 +0.53
AstraZeneca plc (AZN.L) 4,959.50 +107.00
GlaxoSmithKline plc (GSK.L) 1,675.00 +4.50
Eli Lilly and Co (LLY.N) $84.42 +0.06
Amgen, Inc. (AMGN.OQ) $166.04 -1.41
Boston Scientific Corporation (BSX.N) $24.25 -0.02

Earnings vs. Estimates